Risk stratification for disease reactivation after therapy de-escalation/discontinuation in relapsing multiple sclerosis by the VIAADISC score - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40845598/
Risk of disease reactivation after discontinuation from DMF/TERI can be stratified with the VIAADISC score and appears to be safe above age 45-55 and with long-lasting stability. However, risk after...
Proinflammatory Effect of Mesenchymal Stem Cells From Patients With Multiple Sclerosis: Potential Modulation Targets - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40875958/
Our results suggest that blocking ADAM-28 and OPN interaction with cognate receptors or increasing IL-10 reduces the proinflammatory potential of MSCs from people with MS. Similar approaches could be used...
Study shows MSCs from MS patients promote Th17/GM-CSF responses via ADAM28/OPN dysregulation. Natalizumab reduced this proinflammatory effect, underscoring therapeutic relevance of α4β1 blockade and IL-10 modulation in MSC-based MS interventions.
Natalizumab for multiple sclerosis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40767504/
Protocol available via doi.org/10.1002/14651858.CD015123.
Cochrane review of RCTs shows natalizumab significantly reduces relapse risk, disability progression, and MRI activity in RRMS with moderate–high certainty, while benefits in SPMS remain uncertain; safety profile largely comparable to controls.
Cerebral tumefactive demyelinating lesions: clinical spectrum, long-term outcomes, and treatment - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40788335/
Our findings demonstrate that TDLs represent a radiological phenotype associated within a spectrum of neuroinflammatory disorders, with MS being the most frequent underlying diagnosis in our cohort. Although their often...
Retrospective study of 41 patients with tumefactive demyelinating lesions shows MS predominance, favorable long-term outcomes, and benefit from early high-efficacy disease-modifying therapies, including natalizumab, underscoring therapeutic importance in complex neuroinflammatory phenotypes.
A role for DICAM+ mononuclear phagocytes in controlling neuroinflammation in multiple sclerosis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40791582/
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS). In MS, CNS-infiltrating monocytes differentiate to tissue resident macrophages which are found in large numbers within...
Study reveals DICAM⁺ mononuclear phagocytes suppress neuroinflammation in MS. Natalizumab-treated patients retain these cells with increased soluble DICAM, potentially mediating anti-inflammatory effects via cytokine modulation, supporting therapeutic relevance for Tysabri’s immune trafficking blockade.